基因组编辑市场－全球产业规模、份额、趋势、机会及预测（按技术、交付模式、应用、模式、最终用户、地区和竞争格局划分，2021-2031年）

全球基因组编辑市场预计将经历显着成长，从 2025 年的 93.9 亿美元成长到 2031 年的 236.6 亿美元，复合年增长率为 16.65%。

基因组编辑是指透过在特定位点添加、移除或修改遗传物质来改变生物体DNA的一系列技术。推动这一领域快速发展的关键因素包括全球癌症和遗传疾病发病率的不断上升，以及生物技术研究领域的大量资本投入。这一发展动能也体现在近期的产业成就中。根据再生医学联盟预测，细胞和基因治疗领域预计在2024年获得创纪录的九项全球监管核准，这将证实这些先进治疗方法的临床疗效，并提振投资者信心。

儘管取得了这些进展，但市场在安全性和伦理方面仍面临着许多挑战。脱靶效应（导致非预期基因改变）的潜在风险是一大技术障碍，也使监管流程复杂化。因此，製造商必须遵守严格的合规标准，并应对漫长的研发週期。这些障碍增加了营运负担，并可能减缓新型基因编辑产品进入商业市场和广泛应用的速度。

市场驱动因素

公共和私人对基因组研究的投入不断增加，正在推动市场发展，成为将基因编辑理论概念转化为实际临床治疗的重要催化剂。这笔资金的涌入使生技公司能够支持下一代体内疗法所需的高投入研发。例如，大规模创业投资资金筹措已展现出新型工程平台和标靶递送系统的潜力。如同2024年3月新闻稿「Capstan Therapeutics宣布完成1.75亿美元B轮资金筹措」所述，Capstan Therapeutics筹集了1.75亿美元，用于推进其用于治疗自体免疫疾病的体内嵌合体抗原受体T细胞（CAR-T）候选药物的研发。此类投资显示市场对解决商业性化规模化生产的关键递送难题充满信心。

同时，CRISPR 和下一代技术的快速发展正将治疗标靶从遗传性癌症扩展到更广泛的适应症。研发人员正在利用精准的碱基编辑技术和新型酵素来治疗复杂疾病，同时最大限度地降低脱靶风险。这种技术革新在临床研发管线的多元化中显而易见；根据美国基因与细胞治疗学会 (ASGCT) 于 2024 年 10 月发布的《2024 年第三季基因、细胞和 RNA 治疗趋势报告》，51% 的新基因治疗临床试验针对的是非肿瘤领域。此外，主要市场参与者拥有雄厚的财力来支持创新，CRISPR Therapeutics 公司报告称，其 2024 年的现金储备约为 19 亿美元。

市场挑战

与脱靶效应相关的固有风险仍然是阻碍全球基因组编辑市场成长的一大安全障碍。由于非预期基因突变可能导致严重的长期健康问题，包括癌症，监管机构正在实施日益严格的合规标准。这些安全隐患要求进行广泛的临床前检验和长期的病患监测，从而显着延长了研发週期。因此，企业面临着不断增加的营运成本和从研究到人体试验的延误，造成商业化过程中的瓶颈，并阻碍了快速进入市场。

监管放缓的趋势也反映在近期的行业发展趋势。根据美国基因与细胞治疗学会（ASGCT）预测，2025年第三季度，研发速度有所放缓，全球仅启动了125项新的临床试验。这项降幅凸显了精准基因改造安全标准的复杂性如何限制了能够进入临床应用的新治疗方法数量。这些技术和安全方面的障碍需要更谨慎和漫长的研发过程，从而有效地减缓了新产品上市的速度。

市场趋势

将人工智慧 (AI) 融入精准设计正在从根本上改变基因组编辑领域。与依赖细菌资料库探索的传统方法不同，生成式 AI 模型正在创建具有更高特异性的合成编辑系统。这种计算方法透过在实验室检验之前预测并最大限度地减少非预期编辑，直接解决了脱靶效应的挑战。 Profluent 公司在 2024 年 4 月发布的题为「AI 驱动的人类基因组编辑」的新闻稿中宣布了一项突破性进展：该公司的 AI 生成的 OpenCRISPR-1 系统与标准 SpCas9 酶相比，将脱靶编辑减少了 95%，这充分展现了机器学习在提高治疗安全性方面的巨大潜力。

同时，基因编辑作物正迅速走向商业化，其影响范围也从人类治疗扩展到全球粮食安全。农业生物技术开发商正利用CRISPR技术培育具有改良性状和气候变迁适应能力的作物，使其从实验室走向零售市场。该领域的策略整合也在进行中，大型农业公司正与专业的基因编辑公司建立合作关係。例如，根据2024年9月题为「Pairwise与Corteva合作」的新闻稿，Pairwise获得了Corteva 2,500万美元的股权投资，用于加速开发永续农业解决方案，这表明业界对非治疗应用领域充满信心。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球基因组编辑市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依技术分类（CRISPR/Cas9、TALENs/MegaTALs、ZFN、Meganucleases、其他）
  • 依递送方式（体外、体内）
  • 依应用领域（基因工程、临床应用）
  • 按模式（合约开发、内部开发）
  • 依最终用户（生技/製药公司、学术/政府研究机构、合约研究组织）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章 北美基因组编辑市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

第七章 欧洲基因组编辑市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区基因组编辑市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章 中东和非洲基因组编辑市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章 南美洲基因组编辑市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球基因组编辑市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Cibus Inc
• Recombinetics, Inc
• Merck & Co., Inc
• Sangamo Therapeutics Inc
• Editas Medicine Inc
• Precision BioSciences Inc
• CRISPR Therapeutics Inc
• Intellia Therapeutics, Inc
• Caribou Biosciences, Inc
• Takara Bio Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Genome Editing Market is projected to experience substantial growth, increasing from a valuation of USD 9.39 Billion in 2025 to USD 23.66 Billion by 2031, representing a CAGR of 16.65%. Genome editing involves a range of technologies that allow scientists to modify an organism's DNA by adding, removing, or altering genetic material at specific sites. The primary drivers behind this expansion include the growing prevalence of cancer and genetic disorders worldwide, coupled with significant capital investment in biotechnology research. This momentum is highlighted by recent industry achievements; according to the Alliance for Regenerative Medicine, the cell and gene therapy sector secured a record nine global regulatory approvals in 2024, confirming the clinical viability of these advanced therapies and boosting investor confidence.

Despite these advancements, the market faces notable challenges related to safety and ethical concerns. The potential for off-target effects, where unintended genetic modifications occur, serves as a major technical barrier that complicates the regulatory process. Consequently, manufacturers must adhere to strict compliance standards and navigate extended development timelines. These hurdles increase operational burdens and may slow the pace at which new genome editing products enter the commercial market and achieve widespread adoption.

Market Driver

Rising public and private funding for genomic research serves as a major catalyst for the market, facilitating the translation of theoretical gene editing concepts into viable clinical therapies. This influx of capital enables biotechnology firms to support the capital-intensive research and development necessary for next-generation in vivo treatments. For example, large venture capital rounds are validating the potential of novel engineering platforms and targeted delivery systems. As noted in the 'Capstan Therapeutics Announces $175M Series B Financing' press release from March 2024, Capstan Therapeutics raised $175 million to advance its in vivo chimeric antigen receptor T cell candidate for autoimmune disorders. Such investments demonstrate strong market confidence in resolving the delivery challenges essential for commercial scalability.

Simultaneously, rapid advancements in CRISPR and next-generation technologies are broadening the therapeutic scope beyond hereditary cancers to cover a wider range of indications. Developers are utilizing precise base editing techniques and novel enzymes to treat complex conditions while minimizing off-target risks. This technological evolution is evident in the diversification of clinical pipelines; according to the American Society of Gene & Cell Therapy's 'Gene, Cell, + RNA Therapy Landscape Q3 2024 Report' published in October 2024, 51% of new gene therapy trials focused on non-oncology indications. Furthermore, leading market players maintain robust financial health to sustain innovation, with CRISPR Therapeutics reporting a cash position of approximately $1.9 billion in 2024.

Market Challenge

The inherent risk of off-target effects remains a significant safety barrier that restricts the growth of the global genome editing market. Since unintended genetic alterations can lead to severe long-term health issues, such as oncogenesis, regulatory bodies enforce increasingly rigorous compliance standards. These safety concerns necessitate extensive preclinical validation and prolonged patient monitoring, which significantly extends development timelines. Consequently, companies face escalating operational costs and delays in transitioning candidates from research to human testing, creating a bottleneck in the commercial pipeline that discourages rapid market entry.

This regulatory slowdown is reflected in recent industry activity. According to the American Society of Gene & Cell Therapy, the sector experienced a decline in development velocity during the third quarter of 2025, with only 125 new clinical trials initiated globally. This contraction highlights how the complexity of meeting safety thresholds for precise genetic modification limits the volume of new therapies advancing to clinical stages. By necessitating a more cautious and protracted development approach, these technical and safety hurdles effectively dampen the rate at which new products can reach the market.

Market Trends

The integration of artificial intelligence into precision design is fundamentally transforming the genome editing landscape. Moving beyond traditional methods that rely on mining bacterial databases, generative AI models are now creating synthetic editing systems with superior specificity. This computational approach directly tackles the challenge of off-target effects by predicting and minimizing unintended edits before laboratory validation. A significant breakthrough occurred when Profluent announced in their April 2024 press release, 'Editing the Human Genome with AI', that their AI-generated OpenCRISPR-1 system achieved a 95% reduction in off-target editing compared to the standard SpCas9 enzyme, demonstrating the potential of machine learning to enhance therapeutic safety.

Concurrently, the market is seeing the rapid commercialization of gene-edited agricultural crops, extending the industry's influence beyond human therapeutics to global food security. Agricultural biotechnology developers are applying CRISPR technologies to create crops that are resilient to climate change and offer improved traits, moving from experimental trials to retail markets. This sector is also experiencing strategic consolidation as major agricultural companies partner with specialized editing firms. For instance, according to a September 2024 press release titled 'Pairwise Partners with Corteva', Pairwise secured a $25 million equity investment from Corteva to accelerate the development of sustainable agricultural solutions, signaling strong industrial confidence in non-therapeutic applications.

Key Market Players

• Cibus Inc
• Recombinetics, Inc
• Merck & Co., Inc
• Sangamo Therapeutics Inc
• Editas Medicine Inc
• Precision BioSciences Inc
• CRISPR Therapeutics Inc
• Intellia Therapeutics, Inc
• Caribou Biosciences, Inc
• Takara Bio Inc

Report Scope

In this report, the Global Genome Editing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Genome Editing Market, By Technology

• (CRISPR)/Cas9
• TALENs/MegaTALs
• ZFN
• Meganuclease
• Others

Genome Editing Market, By Deliver Mode

• Ex-vivo
• In-vivo

Genome Editing Market, By Application

• Genetic Engineering
• Clinical Applications

Genome Editing Market, By Mode

• Contract
• In-house

Genome Editing Market, By End User

• Biotechnology and pharmaceutical companies
• Academic and government research institutes
• Contract research organizations

Genome Editing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Genome Editing Market.

Available Customizations:

Global Genome Editing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Genome Editing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology ((CRISPR)/Cas9, TALENs/MegaTALs, ZFN, Meganuclease, Others)
  • 5.2.2. By Deliver Mode (Ex-vivo, In-vivo)
  • 5.2.3. By Application (Genetic Engineering, Clinical Applications)
  • 5.2.4. By Mode (Contract, In-house)
  • 5.2.5. By End User (Biotechnology and pharmaceutical companies, Academic and government research institutes, Contract research organizations)
  • 5.2.6. By Region
  • 5.2.7. By Company (2025)
• 5.3. Market Map

6. North America Genome Editing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Deliver Mode
  • 6.2.3. By Application
  • 6.2.4. By Mode
  • 6.2.5. By End User
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Genome Editing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Deliver Mode
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By Mode
      • 6.3.1.2.5. By End User
  • 6.3.2. Canada Genome Editing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Deliver Mode
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By Mode
      • 6.3.2.2.5. By End User
  • 6.3.3. Mexico Genome Editing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Deliver Mode
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By Mode
      • 6.3.3.2.5. By End User

7. Europe Genome Editing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Deliver Mode
  • 7.2.3. By Application
  • 7.2.4. By Mode
  • 7.2.5. By End User
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Genome Editing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Deliver Mode
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By Mode
      • 7.3.1.2.5. By End User
  • 7.3.2. France Genome Editing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Deliver Mode
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By Mode
      • 7.3.2.2.5. By End User
  • 7.3.3. United Kingdom Genome Editing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Deliver Mode
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By Mode
      • 7.3.3.2.5. By End User
  • 7.3.4. Italy Genome Editing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Deliver Mode
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By Mode
      • 7.3.4.2.5. By End User
  • 7.3.5. Spain Genome Editing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Deliver Mode
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By Mode
      • 7.3.5.2.5. By End User

8. Asia Pacific Genome Editing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Deliver Mode
  • 8.2.3. By Application
  • 8.2.4. By Mode
  • 8.2.5. By End User
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Genome Editing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Deliver Mode
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By Mode
      • 8.3.1.2.5. By End User
  • 8.3.2. India Genome Editing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Deliver Mode
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By Mode
      • 8.3.2.2.5. By End User
  • 8.3.3. Japan Genome Editing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Deliver Mode
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By Mode
      • 8.3.3.2.5. By End User
  • 8.3.4. South Korea Genome Editing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By Deliver Mode
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By Mode
      • 8.3.4.2.5. By End User
  • 8.3.5. Australia Genome Editing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By Deliver Mode
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By Mode
      • 8.3.5.2.5. By End User

9. Middle East & Africa Genome Editing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Deliver Mode
  • 9.2.3. By Application
  • 9.2.4. By Mode
  • 9.2.5. By End User
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Genome Editing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Deliver Mode
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By Mode
      • 9.3.1.2.5. By End User
  • 9.3.2. UAE Genome Editing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Deliver Mode
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By Mode
      • 9.3.2.2.5. By End User
  • 9.3.3. South Africa Genome Editing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Deliver Mode
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By Mode
      • 9.3.3.2.5. By End User

10. South America Genome Editing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Deliver Mode
  • 10.2.3. By Application
  • 10.2.4. By Mode
  • 10.2.5. By End User
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Genome Editing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Deliver Mode
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By Mode
      • 10.3.1.2.5. By End User
  • 10.3.2. Colombia Genome Editing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Deliver Mode
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By Mode
      • 10.3.2.2.5. By End User
  • 10.3.3. Argentina Genome Editing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Deliver Mode
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By Mode
      • 10.3.3.2.5. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Genome Editing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Cibus Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Recombinetics, Inc
• 15.3. Merck & Co., Inc
• 15.4. Sangamo Therapeutics Inc
• 15.5. Editas Medicine Inc
• 15.6. Precision BioSciences Inc
• 15.7. CRISPR Therapeutics Inc
• 15.8. Intellia Therapeutics, Inc
• 15.9. Caribou Biosciences, Inc
• 15.10. Takara Bio Inc

16. Strategic Recommendations

17. About Us & Disclaimer